BOSTON--(BUSINESS WIRE)--Ensoma, an in vivo hematopoietic stem cell (HSC) engineering company with a mission to advance the future of medicine through one-time therapies, today announced the closing ...
Lead program advancing to IND filing in H1 2025 for the treatment of X-linked chronic granulomatous disease (X-CGD) will be first in vivo HSC-directed therapy tested in humans Preclinical data to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback